新型冠状病毒感染(COVID-19)疫苗接种后的体外受精与早期妊娠结局
该回顾性队列研究在单中心比较接种COVID-19 mRNA疫苗与未接种患者,发现疫苗接种与控制性卵巢过度刺激的受精率(β=0.02±0.02,P=.20)及单倍体冻融胚胎移植的临床妊娠率(aOR 0.79,95%CI 0.54-1.16)均无显著关联,未观察到对刺激或早期妊娠结局的不良影响。
要点
- 接种COVID-19 mRNA疫苗与控制性卵巢过度刺激的受精率无显著关联(β=0.02±0.02,P=.20)。
- 接种疫苗与单倍体冻融胚胎移植的临床妊娠率无显著关联(aOR 0.79,95%CI 0.54-1.16)。
- 所评估的次要结局包括卵母细胞成熟率、囊胚形成率、整倍体率及妊娠丢失率均无显著关联。
核心结论
- 接种COVID-19 mRNA疫苗与体外受精后刺激或早期妊娠结局的不良影响无关联。
- 研究结果为试图怀孕女性接种COVID-19疫苗的安全性增添了证据。
研究设计与样本
- 回顾性队列研究,纳入单学术中心接受控制性卵巢过度刺激或单倍体冻融胚胎移植的患者。
- 完全接种COVID-19 mRNA疫苗的患者与同一时间段内未接种的患者进行比较。
- 控制性卵巢过度刺激主要结局为受精率,冻融胚胎移植主要结局为临床妊娠率。
主要发现
- 222例接种疫苗与983例未接种患者接受控制性卵巢过度刺激,调整分析显示疫苗接种与受精率无显著关联(β=0.02±0.02,P=.20)。
- 控制性卵巢过度刺激次要结局:获卵数(β=0.01±0.57,P=.99)、成熟卵母细胞数(β=0.26±0.47,P=.58)、成熟卵母细胞比例(β=0.02±0.01,P=.12)、囊胚形成率(β=0.02±0.02,P=.27)、整倍体率(β=0.05±0.03,P=.08)均无显著关联。
- 214例接种疫苗与733例未接种患者接受单倍体冻融胚胎移植,调整分析显示疫苗接种与临床妊娠无显著关联(aOR 0.79,95%CI 0.54-1.16)。
- 冻融胚胎移植次要结局:妊娠(aOR 0.88,95%CI 0.58-1.33)、持续妊娠(aOR 0.90,95%CI 0.61-1.31)、生化妊娠丢失(aOR 1.21,95%CI 0.69-2.14)、临床妊娠丢失(aOR 1.02,95%CI 0.51-2.06)均无显著关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether coronavirus disease 2019 (COVID-19) mRNA vaccination is associated with controlled ovarian hyperstimulation or early pregnancy outcomes. METHODS: This retrospective cohort study included patients who underwent controlled ovarian hyperstimulation or single euploid frozen-thawed embryo transfer at a single academic center. Patients fully vaccinated with a COVID-19 mRNA vaccine were compared with unvaccinated patients who cycled during the same time period. The primary outcome was the fertilization rate for controlled ovarian hyperstimulation and the clinical pregnancy rate for frozen-thawed embryo transfer. Secondary outcomes for controlled ovarian hyperstimulation included eggs retrieved, mature oocytes retrieved, mature oocytes ratio, blastulation rate, and euploid rate. Secondary outcomes for frozen-thawed embryo transfer included pregnancy rate, ongoing pregnancy rate, biochemical pregnancy loss rate, and clinical pregnancy loss rate. RESULTS: Among 222 vaccinated patients and 983 unvaccinated patients who underwent controlled ovarian hyperstimulation cycles between February and September 2021, there was no association on adjusted analysis between COVID-19 vaccination and fertilization rate (β=0.02±0.02, P=.20) or any of the secondary outcomes assessed: eggs retrieved (β=0.01±0.57, P=.99), mature oocytes retrieved (β=0.26±0.47, P=.58), mature oocytes ratio (β=0.02±0.01, P=.12), blastulation rate (β=0.02±0.02, P=.27), or euploid rate (β=0.05±0.03, P=.08). Among 214 vaccinated patients and 733 unvaccinated patients undergoing single euploid frozen-thawed embryo transfer, adjusted analysis demonstrated no significant association between vaccination and clinical pregnancy (adjusted odds ratio [aOR] 0.79, 95% CI 0.54-1.16) or any of the secondary outcomes: pregnancy (aOR 0.88, 95% CI 0.58-1.33), ongoing pregnancy (aOR 0.90, 95% CI 0.61-1.31), biochemical pregnancy loss (aOR 1.21, 95% CI 0.69-2.14), or clinical pregnancy loss (aOR 1.02, 95% CI 0.51-2.06). CONCLUSION: Administration of COVID-19 mRNA vaccines was not associated with an adverse effect on stimulation or early pregnancy outcomes after IVF. Our findings contribute to the growing body of evidence regarding the safety of COVID-19 vaccination in women who are trying to conceive.
引用
- Aharon D, Lederman M, Ghofranian A, et al. In Vitro Fertilization and Early Pregnancy Outcomes After Coronavirus Disease 2019 (COVID-19) Vaccination. Obstet Gynecol. 2022. PMID: 35080199. doi:10.1097/AOG.0000000000004713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。